Growth Metrics

Collegium Pharmaceutical (COLL) Non-Current Deffered Revenue (2024 - 2026)

Collegium Pharmaceutical has reported Non-Current Deffered Revenue over the past 2 years, most recently at $9.1 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 8.89% year-over-year to $9.1 million; the TTM value through Dec 2025 reached $9.1 million, down 8.89%, while the annual FY2025 figure was $9.1 million, 8.89% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $9.1 million at Collegium Pharmaceutical, down from $9.3 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $10.0 million in Q3 2024 and troughed at $9.1 million in Q4 2025.